Avantor Inc (AVTR) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of Avantor Inc $8.97, price $15.38, upside -41.7%, quality 46 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Avantor Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range $7.41 – $44.01 · fair‑value band $3.07 – $17.00 · the $15.38 price screens above the $8.97 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Avantor in your weekly email
Every Wednesday you see whether Avantor is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Avantor, Inc. engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa.
Show more
Avantor, Inc. engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, and fluid handling tips. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, peristaltic pumps, and critical environment supplies. In addition, the company offers services and specialty procurements comprising onsite lab and production, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services. Further, it provides scientific research support services, such as DNA extraction, bioreactor servicing, clinical and biorepository, compound management, cleanroom control, monitoring, maintenance, and sanitization services. The company was founded in 1904 and is headquartered in Radnor, Pennsylvania.
Stock analysis
Avantor Inc (AVTR) currently trades at $15.38, while our model-based Fair Value estimate is $8.97, implying the stock looks roughly 71.5% overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of $9.01 per share, and 2 of the 9 models we run sit above the $15.38 price.
Bear case: the Multiples group reads lowest at $4.23, and 7 of the 9 models stay below the price. Evidence for this calculation is medium.
Scenario range: $3.07 (bear) to $17.00 (bull), the price of $15.38 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 46/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Avantor Inc reported revenue of $6.6B in FY2025 versus $7.4B in FY2021, a compound −3.0%/yr. Reported net income was −$530M in FY2025.
Key figures
Market cap $10.4B · P/S ratio 1.15 · EPS (TTM) $−0.8100 · Net margin −8.1% · Return on equity −9.4% · Return on assets (EBIT) 5.5% · Operating margin 6.3% · Revenue (TTM) $6.6B.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 43 out of 100 (low confidence).
What moves the price
The share trades about 3% below its 52-week high and 108% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −13% fair-value upside, at −42%, AVTR screens richer than that median.
Fair Value models
Bear $3.07Fair Value $8.97Bull $17.00
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.24/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
−3.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.5%
Start year 2020 (pandemic). Over 10 years: +26.3% a year
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+26.3%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
11.1% (2020) → −3.8% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+15.7%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+1.5%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +13.0% a year for the price and −0.9% for the forecasts.
News mood ⓘNews mood, the average tone of recent news (97 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Hype
Recent news coverage is unusually upbeat, far more positive than stocks are typically covered.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 204 stocks
Beats the industry median on 1/10 measures
Overall it trails its industry peers.
Valuation
Quality Score46 · Below median
Fair Value upside−42% · Below median
Profitability
Return on assets3% · Below median
Net margin (TTM)−8% · Bottom 25%
Operating margin (TTM)6% · Below median
Growth and dividend
Revenue growth0% · Below median
Balance sheet
Debt / equity0.70× · Highest 25%
Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper
P/B1.88× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (TTM)1.60× · Cheaper than median
P/FCF21.1× · Pricier than median
EV/EBITDA14.8× · Pricier than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 14
FUTURE (revenue growth)0· sector 31
PAST (return on equity)0· sector 25
HEALTH (low debt)65· sector 96
DIVIDEND (yield)0· sector 33
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Avantor Inc Fair Value". https://www.fairvalue-calculator.com/stock/AVTR
Frequently asked questions
Is Avantor Inc (AVTR) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $8.97 versus a price of $15.38, about −42% upside (overvalued).
What is the fair value of AVTR?
Our model-based fair value for Avantor Inc is $8.97 (as of Sep 24, 2026), built from audited fundamentals. The current price: $15.38.
What is the quality score of AVTR?
Avantor Inc has a Quality Score of 46/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Avantor Inc (AVTR)?
Our model-based price target is the fair value of $8.97 (as of Sep 24, 2026) from 9 valuation models. Cautious scenario $3.07, optimistic scenario $17.00. It is a calculation from audited fundamentals, not an analyst target.
What is the Avantor Inc stock forecast for 2026?
Our models put fair value at $8.97, about −42% upside versus a price of $15.38 (overvalued). Cautious scenario $3.07, optimistic scenario $17.00. The calculation is refreshed regularly with new filings.
What is the revenue of Avantor Inc (AVTR)?
Avantor Inc reported trailing-twelve-month revenue of about $6.6B (latest available figure, as of Sep 24, 2026).
What growth is priced into Avantor Inc (AVTR)?
For today's price to be fair in a discounted-cash-flow model, Avantor Inc would have to grow free cash flow by +15.7 % per year for five years (discount rate 9.6 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +0.5 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of AVTR use?
Our models discount Avantor Inc at 9.6 %: a base by market capitalisation (mid), damped by beta 0.94, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Avantor Inc that is +15.7 % per year a year over ten years, using the same discount rate (9.6 %) and the same formula as our fair value.
How much growth has Avantor Inc (AVTR) delivered so far?
Over the past 5 years revenue at Avantor Inc grew +0.5 % a year. The price currently implies +15.7 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Avantor Inc (AVTR) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Avantor Inc (+15.7 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Avantor Inc (AVTR)?
The free-cash-flow yield on the price is 4.74 %: that much free cash flow Avantor Inc produces per unit of market value. When it exceeds the discount rate of our models (9.6 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Avantor Inc (AVTR)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Avantor Inc it is $8.97 per share (as of Sep 24, 2026), against a price of $15.38. It is the blended result of 9 valuation models (cash flow, earnings, asset, dividend).
Is Avantor Inc stock overvalued or undervalued in 2026?
As of Sep 24, 2026, AVTR trades above its calculated fair value: price $15.38, fair value $8.97, a gap of about −42% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of AVTR?
No. The price is what the market pays today ($15.38); the fair value is what the company's own numbers justify ($8.97). For Avantor Inc the two are $6.41 per share apart. That gap is exactly why we show both numbers side by side.
How much is Avantor Inc worth?
The market values Avantor Inc at about $10.4B (market capitalisation, as of Sep 24, 2026). Per share that is $15.38; our models calculate a fair value of $8.97 per share.
What do the bullish and bearish scenarios say about AVTR?
Our models span a range for Avantor Inc: cautious scenario $3.07, base $8.97, optimistic $17.00 per share (as of Sep 24, 2026, price $15.38). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Avantor Inc (AVTR)?
Balance-sheet figures for Avantor Inc (as of Sep 24, 2026): return on equity −9.4%, debt of 0.70 per unit of equity. They feed the Quality Score of 46/100, which measures business quality independently of the share price.
How far is AVTR from its 52-week high?
Avantor Inc trades at $15.38, about 3% below its 52-week high of $15.86 and 108% above the low of $7.41 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of $8.97 is for.
Which stocks are comparable to Avantor Inc?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Medline Inc, Becton, Dickinson and Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Avantor Inc stock attractive at the current price?
The data as of Sep 24, 2026: price $15.38, calculated fair value $8.97 (−42%), Quality Score 46/100, from 9 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of AVTR calculated?
We run Avantor Inc through 9 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $8.97, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. Avantor Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Avantor Inc (AVTR)?
The closing price on Sep 24, 2026 was $15.38. Our model-based fair value is $8.97, about −42% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Avantor Inc right now?
The model range is unusually wide ($3.07 to $17.00). The outcome hinges heavily on assumptions, so read the point estimate with caution. Solid but not exceptional quality (46/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Avantor Inc
How large is the market capitalisation of Avantor Inc (AVTR)?
The market capitalisation of Avantor Inc is $10.4B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Avantor Inc (AVTR)?
The price-to-sales ratio of Avantor Inc is 1.15 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Avantor Inc (AVTR)?
Earnings per share at Avantor Inc are $−0.8100. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Avantor Inc (AVTR)?
The net margin of Avantor Inc is −8.1% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Avantor Inc (AVTR)?
The return on equity (ROE) of Avantor Inc is −9.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Avantor Inc (AVTR)?
On an EBIT basis the return on assets of Avantor Inc is 5.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Avantor Inc (AVTR)?
The operating margin of Avantor Inc is 6.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast are earnings growing at Avantor Inc (AVTR)?
Earnings per share at Avantor Inc are growing −33.3% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Avantor Inc (AVTR) carry?
The net debt of Avantor Inc is $3.6B (fiscal year 2025, ≈ 7.2 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Avantor Inc in the live analysis
One click puts Avantor Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Some data
Sep 24, 2026